BR112012027793A2 - método para a purificação de uma proteína de ligação de cátion divalente, e, kit - Google Patents

método para a purificação de uma proteína de ligação de cátion divalente, e, kit

Info

Publication number
BR112012027793A2
BR112012027793A2 BR112012027793A BR112012027793A BR112012027793A2 BR 112012027793 A2 BR112012027793 A2 BR 112012027793A2 BR 112012027793 A BR112012027793 A BR 112012027793A BR 112012027793 A BR112012027793 A BR 112012027793A BR 112012027793 A2 BR112012027793 A2 BR 112012027793A2
Authority
BR
Brazil
Prior art keywords
divalent cation
kit
purifying
cation binding
binding protein
Prior art date
Application number
BR112012027793A
Other languages
English (en)
Other versions
BR112012027793B1 (pt
BR112012027793A8 (pt
Inventor
Artur Mitterer
Christian Fiedler
Meinhard Hasslacher
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of BR112012027793A2 publication Critical patent/BR112012027793A2/pt
Publication of BR112012027793A8 publication Critical patent/BR112012027793A8/pt
Publication of BR112012027793B1 publication Critical patent/BR112012027793B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

método para a purificação de uma proteína de ligação de cátion divalente, e, kit. a presente invenção se refere a um método para a purificação de proteínas de ligação de cátion divalente com alta pureza em um material de resina de troca aniônica, a proteínas de ligação de cátion divalente obteníveis pelo dito método, e a um kit compreendendo meios para realizar o dito método.
BR112012027793-6A 2010-04-29 2011-04-29 Método para a purificação de uma proteína de ligação de cátion divalente BR112012027793B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32948710P 2010-04-29 2010-04-29
US61/329,487 2010-04-29
PCT/EP2011/056832 WO2011135071A1 (en) 2010-04-29 2011-04-29 Purification method for divalent cation binding proteins on anion exchange resin

Publications (3)

Publication Number Publication Date
BR112012027793A2 true BR112012027793A2 (pt) 2016-08-02
BR112012027793A8 BR112012027793A8 (pt) 2018-06-05
BR112012027793B1 BR112012027793B1 (pt) 2022-10-11

Family

ID=44625749

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012027793-6A BR112012027793B1 (pt) 2010-04-29 2011-04-29 Método para a purificação de uma proteína de ligação de cátion divalente

Country Status (16)

Country Link
US (1) US10202416B2 (pt)
EP (1) EP2563805B8 (pt)
JP (1) JP5883849B2 (pt)
KR (1) KR101780518B1 (pt)
CN (2) CN103025757A (pt)
AU (1) AU2011247567B2 (pt)
BR (1) BR112012027793B1 (pt)
CA (1) CA2797614A1 (pt)
DK (1) DK2563805T3 (pt)
ES (1) ES2790884T3 (pt)
MX (1) MX336728B (pt)
NZ (1) NZ603289A (pt)
PL (1) PL2563805T3 (pt)
PT (1) PT2563805T (pt)
SG (1) SG185005A1 (pt)
WO (1) WO2011135071A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011247567B2 (en) 2010-04-29 2014-06-19 Takeda Pharmaceutical Company Limited Purification method for divalent cation binding proteins on anion exchange resin
EP2748179B1 (en) 2011-10-14 2021-12-29 Takeda Pharmaceutical Company Limited Protein purification by anion exchange chromatography
US9701710B2 (en) 2011-10-14 2017-07-11 Baxalta Incorporated Protein purification by anion exchange chromatography
CN103509082B (zh) * 2012-06-15 2016-03-02 郭怀祖 一种糖基化蛋白和非糖基化蛋白的分离方法
EP2970376B1 (en) * 2013-03-15 2018-05-23 Baxalta Incorporated Purification method for vitamin k dependent proteins by anion exchange chromatography
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB2552724B (en) * 2015-09-17 2020-05-06 Annexin Pharmaceuticals Ab Purification of Annexin A5 by anion exchange and affinity chromatography
GB2552853B (en) * 2015-09-17 2018-11-21 Annexin Pharmaceuticals Ab Purification of Annexin A5 from a composition that includes a calcium ion chelator
WO2021002275A1 (ja) * 2019-07-02 2021-01-07 日本メジフィジックス株式会社 ２２６Ｒａ含有溶液の精製方法、２２６Ｒａターゲットの製造方法および２２５Ａｃの製造方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318754D0 (en) * 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
ES2152953T3 (es) 1992-08-27 2001-02-16 Sanquin Bloedvoorziening Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina.
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
DE4406515C1 (de) 1994-02-28 1995-10-19 Immuno Ag Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine
US5714583A (en) * 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
JPH10150980A (ja) * 1996-11-20 1998-06-09 Chemo Sero Therapeut Res Inst プロトロンビンの精製方法
DE69841459D1 (en) 1997-02-14 2010-03-11 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
GB9902000D0 (en) * 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
CN1250567C (zh) 2000-07-21 2006-04-12 财团法人化学及血清疗法研究所 钙离子结合蛋白的提纯方法
US20040106779A1 (en) * 2002-12-03 2004-06-03 Bigler Douglas E. Modified factor IX preparation
US20090042784A1 (en) * 2004-09-29 2009-02-12 Janus Krarup Purification of a Drug Substance of a Factor VII Polypeptide by Removal of DesGla-Factor VII Polypeptide Structures
BRPI0519626A2 (pt) * 2004-12-23 2009-02-25 Novo Nordisk Healthcare Ag mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse
EP1924688A1 (en) * 2005-09-01 2008-05-28 Novo Nordisk Health Care AG Purification of coagulation factor vii polypeptides
FR2901796A1 (fr) * 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
DK2125866T3 (da) 2007-02-28 2013-07-29 Baxter Int Fremgangsmåde til rensning af rekombinant blodkoagulationsfaktor IX, som er beriget med sulfaterede og/eller phosphorylerede molekyler
CN102666568B (zh) 2009-12-18 2015-12-09 杰特有限公司 纯化多肽的方法
AU2011247567B2 (en) 2010-04-29 2014-06-19 Takeda Pharmaceutical Company Limited Purification method for divalent cation binding proteins on anion exchange resin
US9701710B2 (en) 2011-10-14 2017-07-11 Baxalta Incorporated Protein purification by anion exchange chromatography
EP2748179B1 (en) 2011-10-14 2021-12-29 Takeda Pharmaceutical Company Limited Protein purification by anion exchange chromatography

Also Published As

Publication number Publication date
AU2011247567B2 (en) 2014-06-19
EP2563805A1 (en) 2013-03-06
SG185005A1 (en) 2012-11-29
CN103025757A (zh) 2013-04-03
PT2563805T (pt) 2020-05-18
ES2790884T3 (es) 2020-10-29
KR101780518B1 (ko) 2017-09-21
US20120108513A1 (en) 2012-05-03
JP2013525411A (ja) 2013-06-20
BR112012027793B1 (pt) 2022-10-11
CA2797614A1 (en) 2011-11-03
US10202416B2 (en) 2019-02-12
CN106967150A (zh) 2017-07-21
EP2563805B1 (en) 2020-02-26
BR112012027793A8 (pt) 2018-06-05
EP2563805B8 (en) 2020-04-15
CN106967150B (zh) 2020-12-04
WO2011135071A1 (en) 2011-11-03
MX2012012621A (es) 2013-05-06
PL2563805T3 (pl) 2020-08-10
KR20130062938A (ko) 2013-06-13
NZ603289A (en) 2014-07-25
DK2563805T3 (da) 2020-05-18
MX336728B (es) 2016-01-27
JP5883849B2 (ja) 2016-03-15

Similar Documents

Publication Publication Date Title
BR112012027793A2 (pt) método para a purificação de uma proteína de ligação de cátion divalente, e, kit
CY1122278T1 (el) Αντι il-36r αντισωματα
ECSP13012649A (es) Anticuerpos ANTI-IL-23
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
CY1122978T1 (el) Αντισωματα εναντι-vla-4
BR112014007487A2 (pt) peptídeos terapêuticos
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
EA201600338A1 (ru) Биспецифическая связывающая молекула, связывающаяся с vegf и ang2
DK2723771T3 (da) Serumalbuminbindende proteiner
MX2013012844A (es) Secuencias de aminoacidos dirigidas contra il-17a, il-17f y/o il-17a/f y polipeptidos que comprenden las mismas.
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
AR088512A1 (es) Anticuerpos dirigidos contra el tnf
BR112012029904A2 (pt) métodos de purificação de polipeptídeos
MX2015011075A (es) Peptidos terapeuticos.
BR112012023015A2 (pt) imunoensaios para lenalidomida e talidomida
CO7020862A2 (es) Proteinas de unión al antígeno cd27l
BR112012004697B8 (pt) método para purificar um polipeptídeo compreendendo uma região ch2/ch3
EP2791362A4 (en) PROTEINS WITH MRSA PBP2A AND FRAGMENTS THEREOF, NUCLEIC ACIDS FOR CODING THEREOF AND PREPARATIONS AND THEIR USE FOR THE PREVENTION AND TREATMENT OF MRSA INFECTIONS
AR090923A1 (es) Anticuerpos anti-il-23
PH12015501687A1 (en) Novel binding proteins from pcsk9
WO2012068317A3 (en) Methods for producing recombinant proteins
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
BR112013028015A2 (pt) composição de resina epóxi, e, método para ligar pelo menos dois substratos juntos
AR123070A2 (es) Anticuerpos anti-il-23
BR112012008154A2 (pt) plgf-1 na forma homodimérica

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: BAXTER INTERNATIONAL INC (US) , BAXTER HEALTHCARE

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAXALTA INCORPORATED (US) ; BAXALTA GMBH (CH)

B15G Petition not considered as such [chapter 15.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: BAXALTA GMBH (CH) ; BAXALTA INCORPORATED (US)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2652 DE 03/11/2021 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/04/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.